Introduction
The COVID-19 pandemic has intensified global interest in the human immune system. While traditional herbal medicines (THMs) are known for their immunomodulatory potential—offering multi-target effects with low toxicity—they often suffer from poor bioavailability. Many active compounds, such as complex polysaccharides and saponins, are too large or structurally intricate for efficient gut absorption.
Lactic acid bacteria (LAB) fermentation has emerged as a transformative strategy to overcome these hurdles. By utilizing "Generally Recognized as Safe" (GRAS) microbes as microscopic chemists, researchers can biotransform herbal substrates into more potent, bioavailable metabolites. This approach not only preserves the medicinal value but actively re-engineers it to enhance immune regulation through both innate and adaptive pathways.
The Synergistic Biotransformation
The relationship between LAB and herbal medicines is a bidirectional "handshake." Herbal ingredients often serve as prebiotics, promoting the growth of LAB and the production of beneficial metabolites like short-chain fatty acids (SCFAs), exopolysaccharides (EPS), and bacteriocins. Conversely, LAB enzymes (e.g., $\beta$-glucosidase) perform "deglycosylation," stripping sugar chains from large herbal molecules to create smaller, more active aglycones that are easier for the body to utilize.
This biotransformation effectively optimizes natural products. For instance, fermentation can reduce the molecular weight of polysaccharides by up to 50%, facilitating better binding to immune cell receptors like TLR4 to trigger defense responses.
Mechanisms of Immunomodulation
Fermented herbal medicines regulate the immune response through several key mechanisms:
- Innate Immune Activation: Enhanced macrophage phagocytosis and natural killer (NK) cell cytotoxicity.
- Adaptive Immune Regulation: Balancing Th1/Th2 responses and increasing the production of antibodies such as IgA, IgG, and IgM.
- Gut Homeostasis: Upregulating tight junction proteins (e.g., occludin, ZO-1) to reinforce the intestinal barrier and prevent systemic inflammation.
- Metabolic Synergy: The production of SCFAs and EPS by LAB adds a secondary layer of immunomodulatory activity beyond the modified herbal compounds themselves.
Key Experimental Findings
Research across various models—from mouse macrophage cell lines (RAW 264.7) to human clinical trials—demonstrates significant quantitative improvements in potency following fermentation.
Notable highlights include:
- Red Ginseng: Fermentation increased bioavailable ginsenosides (CK, Rh1, Rh2) by 67.5% and significantly raised serum IgA levels in human subjects compared to unfermented versions.
- Astragalus: Fermented polysaccharides showed a 26.4% free radical scavenging rate, outperforming the 20.8% rate of unfermented versions.
- Gynostemma: Fermentation led to a significant increase in the "immune organ index" and boosted antibody production in immunosuppressed models.
Future Directions
Despite promising results, several challenges remain. Future research should focus on elucidating complex chemical reactions like demethylation, optimizing strains by exploring "endophytic" LAB naturally found within medicinal plants, and tracking the survival of live LAB in the gut post-ingestion. Integrating metabolomics and transcriptomics will be essential to fully map the chemical-to-genetic pathways of these fermented products.
By bridging traditional wisdom with modern microbial biotechnology, LAB-mediated fermentation offers a powerful new frontier for natural immunotherapy.
Summary updated